Drug Profile

REV 102

Alternative Names: REV-102

Latest Information Update: 20 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Rallybio
Developer Rallybio; Recursion Pharmaceuticals
Class Small molecules
Mechanism of Action Ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Hypophosphatasia

Most Recent Events

13 Mar 2025 Preclinical trials in Hypophosphatasia in USA (PO), prior to March 2025
13 Mar 2025 Recursion Pharmaceuticals plans to initiate a phase I trial for Hypophosphatasia (PO), in 2026
10 Jan 2025 Recursion Pharmaceuticals plans to initiate investigational new drug application (IND)-enabling studies in 2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com